STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds
Most new cancer medicines approved by European regulators over a recent four-year period do not offer high clinical benefit, a new analysis finds.
A new analysis reveals that most new cancer drugs approved by European regulators over the past four years do not provide high clinical benefit, with only 31% of 97 approved treatments offering a high level of benefit. Just nine of these 63 cancer drugs received the top grade from measurement tools used by the European Society for Medical Oncology.
Only 19 of the 63 cancer drugs had at least one high-benefit indication. This discrepancy is attributed to just five drugmakers, four of which are based in Asia (China or Japan), accounting for over half of all high-benefit indications for medications approved by European regulators between January 2022 and July 2026.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
